If you work in polymer chemistry, you already know itaconic acid. It is a workhorse industrial compound, a dicarboxylic acid with a double bond that makes it perfect for manufacturing plastics, resins, and synthetic fibers. China produces more of it than any other country, mostly through fermentation using fungi and yeasts.
What most people do not realize is that your own body makes itaconic acid too. And when it does, it is not making plastic. It is fighting off infections, calming inflammation, and possibly even slowing tumor growth.
The story of itaconic acid as a biological molecule is surprisingly recent. For over 170 years after Swiss chemist Samuel Baup first isolated it in 1836, scientists thought of it strictly as an industrial chemical. It was not until 2011 that researchers detected it in mammalian immune cells. Then in 2013, a team led by Michelucci published the key breakthrough: inside activated macrophages, an enzyme called IRG1 (immune-responsive gene 1 protein, also known as CAD, cis-aconitate decarboxylase) converts the TCA cycle intermediate cis-aconitate into itaconic acid.
That discovery cracked open an entire field. Suddenly a humble industrial compound had a second life as an immune signaling molecule. Here is what we have learned since.
Itaconic Acid as an Antibiotic
Bacteria rely on a metabolic shortcut called the glyoxylate cycle, something animals simply do not have. At the center of this cycle sits isocitrate lyase (ICL), an enzyme that lets certain pathogens survive inside host cells by feeding on fatty acid breakdown products. Mycobacterium tuberculosis, the bug behind TB, depends on ICL for persistence. Salmonella uses it too.
Itaconic acid goes straight for this bacterial vulnerability. It inhibits ICL, cutting off the pathogen’s metabolic lifeline. But the damage does not stop there. ICL also has methylisocitrate lyase (MCL) activity, which bacteria need to detoxify propionyl-CoA, a toxic byproduct generated when they metabolize host cholesterol. Block ICL, and you hit the bacteria twice: starve them and poison them at the same time.
Michelucci’s group also found that itaconic acid combined with propionic acid produces a synergistic antibacterial effect. And since itaconic acid is something mammalian cells produce endogenously, it has a genuine advantage over conventional antibiotics: no synthetic residues, no environmental contamination. That opens doors for applications in food safety and animal feed, not just pharmaceuticals.
One open question worth watching: does itaconic acid interact with other organic acids, synergistically or antagonistically? Nobody has mapped that thoroughly yet.
A New Angle on Cancer
Tumors are metabolic monsters. Compared to normal cells, cancer cells burn through glucose at an alarming rate (the Warburg effect), and their metabolic byproducts reshape the immune landscape around them. Lactate, for instance, pushes macrophages toward a tumor-friendly phenotype, ramping up VEGF and arginase activity. The immune system gets recruited to help the tumor grow.
Weiss and colleagues reported in 2018 that macrophages from tumor-bearing mice had significantly elevated itaconic acid levels. At first glance, that seems confusing. Is itaconic acid helping the tumor or fighting it?
The answer, based on their follow-up work, leans toward “helping”, at least in peritoneal tumors. When they silenced IRG1 with shRNA to block itaconic acid production, tumor growth slowed. The mechanism appears to run through oxidative phosphorylation (OXPHOS): itaconic acid promotes ROS production, which activates the MAPK signaling cascade in tumor cells and drives proliferation.
That makes itaconic acid and ROS both potential therapeutic targets. If you could selectively dial down itaconic acid production in the tumor microenvironment, you might take away one of the tumor’s growth signals. It is a different kind of anti-cancer strategy: not directly killing cancer cells, but removing a metabolic boost they have learned to exploit.
Cooling Down Inflammation
When your body faces an infection or tissue damage, macrophages release itaconic acid. This is not a side effect. It is part of the resolution plan.
Two landmark papers published back-to-back in Nature in 2018 laid out the anti-inflammatory circuitry. The first, from Mills et al., showed that itaconic acid activates Nrf2 (nuclear factor erythroid 2-related factor 2), which is arguably the most important transcription factor your cells have for handling oxidative and electrophilic stress.
Under normal conditions, Nrf2 sits in the cytoplasm tethered to KEAP1, which constantly tags it for degradation. When itaconic acid shows up, it alkylates specific cysteine residues on KEAP1. That modification breaks the KEAP1-Nrf2 handshake, freeing Nrf2 to travel into the nucleus and switch on a whole battery of protective genes. Macrophages treated with itaconic acid produce fewer pro-inflammatory cytokines and less ROS. In septic mice, that translates directly to better early survival.
The second paper, from Bambouskova et al., uncovered a parallel pathway through IκBζ-ATF3. When toll-like receptors (TLRs) activate immune cells, they trigger a secondary transcriptional wave regulated by IκBζ. Itaconic acid shuts IκBζ down, not at the transcriptional level but post-transcriptionally, and it does so by upregulating ATF3. The Nrf2 pathway is not involved here. Delete ATF3, and itaconic acid can no longer suppress IκBζ.
Two separate anti-inflammatory circuits, both triggered by the same small molecule. It suggests real therapeutic potential for chronic inflammatory conditions and sepsis.
Antioxidant Protection
Oxidative stress happens when reactive oxygen species (superoxide, hydroxyl radicals, hydrogen peroxide, peroxynitrite) pile up faster than your antioxidant systems can clear them. Low-level ROS is fine; it even helps with cell signaling. High-level ROS destroys proteins, lipids, and DNA, eventually triggering apoptosis.
The KEAP1-Nrf2-ARE axis is the main route through which itaconic acid delivers antioxidant effects. Once Nrf2 reaches the nucleus, it binds to antioxidant response elements (ARE) and drives expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and the catalytic subunit of glutamate-cysteine ligase (GCLC). These are core components of cellular antioxidant defense.
The practical angle goes beyond pharma. If itaconic acid or its derivatives can stabilize oxidative damage, they might find uses as natural preservatives in food processing, as feed additives to extend shelf life, or in packaging materials that actively resist oxidation.
Fighting Viruses Indirectly
Itaconic acid does not attack viruses directly. Instead, it reshapes cellular metabolism to make the host less hospitable.
One route runs through Nrf2 again. Viral nucleic acid sensors like cGAS (for DNA viruses) and RIG-I/MDA-5 (for RNA viruses) feed into the STING adaptor protein, which triggers IFN-α/β production. Some interferon is essential for antiviral defense, but too much causes tissue pathology. Olagnier et al. showed in 2018 that itaconic acid-induced Nrf2 activation suppresses STING expression, dialing back the interferon response to a safer level.
The second route involves RIPK-mediated necroptosis. When a virus infects a cell, RIPK signaling can trigger programmed necrosis. Daniels et al. found that RIPK activation upregulates IRG1, boosting itaconic acid production, which then inhibits succinate dehydrogenase (SDH) in the TCA cycle. The resulting metabolic shift suppresses viral replication in neurons.
Most recently, Sethy et al. screened 20,000 compounds and found an itaconic acid derivative with potent anti-influenza A activity (EC50 = 0.14 μmol/L) and a selectivity index above 785. They went on to synthesize a whole series of derivatives. The best candidate works by blocking viral replication. That kind of potency and selectivity puts itaconic acid derivatives on the map as antiviral drug leads, and the indirect mechanism, which works through the host rather than the virus, may reduce the risk of resistance developing.
How Itaconic Acid Reshapes Metabolism
Beyond immunity, itaconic acid directly acts on core energy metabolism at two choke points.
The first is glycolysis. Phosphofructokinase-1 (PFK1) catalyzes the irreversible conversion of fructose-6-phosphate to fructose-1,6-bisphosphate. That is the committed step of glycolysis. PFK2 makes fructose-2,6-bisphosphate, which is the most potent allosteric activator of PFK1. Itaconic acid inhibits PFK2. When PFK2 activity drops, fructose-2,6-bisphosphate levels fall, PFK1 slows down, and the entire glycolytic pipeline throttles back. Less pyruvate, less acetyl-CoA feeding into the TCA cycle.
During immune activation, this makes adaptive sense. Think of it as an energy valve: when your macrophages are busy fighting an infection, itaconic acid shuts down unnecessary fuel consumption, preserving resources and potentially favoring protein retention over fat synthesis. Way back in the 1950s, Booth et al. showed that dietary itaconic acid in mice suppressed the conversion of glucose to fat, reduced visceral fat deposition, and helped maintain body protein balance.
The second choke point is the TCA cycle itself. Itaconic acid inhibits SDH (Complex II of the electron transport chain), causing succinate to accumulate. That succinate buildup activates HIF-1α, which reprograms cellular metabolism toward glycolysis by upregulating glucose transporters (GLUT1, GLUT3) and glycolytic enzymes. Under inflammatory conditions, where oxygen tension already drops at the infection site, HIF-1α activation reinforces the glycolytic shift that activated immune cells depend on.
Most of this metabolic work has been done in mice and cell lines. Whether itaconic acid can improve stress resilience and production performance in livestock remains an open and commercially interesting question.
What Comes Next
Itaconic acid has come a long way from being just another industrial monomer. Mammalian cells make it on purpose, and when they do, it functions as a multi-tool: antibacterial agent, metabolic modulator, inflammation brake, antioxidant, antiviral, and metabolic valve.
Here is what I am watching:
- Mapping the full signaling network, including cross-talk between the Nrf2 and ATF3 pathways
- Developing itaconic acid derivatives as drug candidates (Sethy’s anti-influenza work is a solid proof of concept)
- Exploring applications in livestock feed to reduce stress and improve production efficiency
- Understanding interactions with other organic acids for synergistic formulations
There is a bigger picture here too. Metabolites are not just passive intermediates. They can be active signaling molecules. Itaconic acid is one of the clearest examples of a TCA cycle intermediate moonlighting as an immune regulator. It probably will not be the last one we find.